Tag Liver Diseases

Gilead Sciences acquires CymaBay Therapeutics

Gilead Sciences and CymaBay Therapeutics announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for…

Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for NASH/MASH.

Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of…